Influenza Vaccination and COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study

Veronese, Nicola; Smith, Lee; Gennaro, Francesco Di; Bruyère, Olivier; Yang, Lin; Demurtas, Jacopo; Maggi, Stefania; Sabico, Shaun; Al-Daghri, Nasser M.; Barbagallo, Mario; Domínguez, Ligia J.; Koyanagi, Ai

doi:10.3390/vaccines10060899

Cited by 10 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccination status against influenza or COVID-19 vaccines can affect the immune status of COVID-19 patients and uninfected individuals, which is the primary factor affecting the severity of the disease. [26,27] Patient vaccinations were not included in this analysis since this information was missing from the electronic medical records.…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of COVID-19 among 391 hospitalized patients in the Henan province of China

et al. 2023

View full text Add to dashboard Cite

This study investigated the clinical characteristics and risk factors of coronavirus disease 2019 (COVID-19) in patients in designated hospitals (Port Hospital) in the Henan province. A total of 391 COVID-19 patients with complete case information from August 6, 2021 to February 26, 2022 were selected. Logistic regression was used to analyze the differences between the clinical types, ages, and sex of the patients. Multivariate regression analysis of the severe group indicated that underlying diseases [odds ratio (OR):6.76, 95% confidence interval (CI):1.83–24.93], increased urea levels (OR: 1.41, 95% CI: 1.04–1.91), old age (OR: 1.05, 95% CI: 1.00–1.10), and increased lactic dehydrogenase (OR: 1.02, 95% CI: 1.01–1.03) levels and decreased hemoglobin (OR: 0.95, 95% CI: 0.91–1.00) levels were predictors of illness severity. Multivariate regression analysis for those > 50 years of age showed that underlying diseases (OR: 7.06, 95% CI: 2.79–17.89) and increased urea (OR: 1.91, 95% CI: 1.47–2.48), total bilirubin (OR: 1.14, 95% CI: 1.08–1.21), total protein (OR: 1.08, 95% CI: 1.00–1.17), and lactic dehydrogenase (OR: 1.01, 95% CI: 1.00–1.02) levels and decreased albumin (OR: 0.66, 95% CI: 0.58–0.76) levels were characteristics of COVID-19. Multivariate regression analysis stratified by sex showed that the characteristics of COVID-19 patients were increased white blood cell count in males (OR: 0.66, 95% CI: 0.55–0.78) as well as increased creatinine levels (OR: 0.89, 95% CI: 0.87–0.91). This retrospective analysis provides useful information to support the clinical management of patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of COVID-19 among 391 hospitalized patients in the Henan province of China

et al. 2023

View full text Add to dashboard Cite

show abstract

“…6 Influenza vaccination, particularly for vulnerable, older people, will have added importance this winter given the possibility of further waves of the COVID-19 pandemic. 7 Strategies to improve vaccination rates are therefore desirable. While hospital-based interventions in this regard have been shown to be successful, 8 there remains a need for organisational or system-based interventions to increase vaccination uptake.…”

Section: Introductionmentioning

confidence: 99%

An electronic medical record reminder is independently associated with improved opportunistic influenza vaccination rates for older inpatients

Chapman

Kelly

Piggott

et al. 2023

Journal of the Royal College of Physicians of Edinburgh

View full text Add to dashboard Cite

Background: Influenza vaccination will have added importance this winter given the possibility of further waves of the COVID-19 pandemic. This study examines the impact of an electronic medical record (EMR) reminder on influenza vaccine uptake among eligible hospital inpatients. Methods: We included a convenience sample of 750 adults (median age 77 years) who are eligible for influenza vaccination (⩾65 years and/or length of stay >30 days). A live electronic dashboard identified patients eligible for vaccination, prompting reminders sent to the clinical teams via the EMR. Results: The EMR reminder was associated with almost a 50% higher likelihood of vaccination after adjusting for other covariates (odds ratio 1.48 (95% confidence interval 1.00–2.20); p = 0.048). Discussion: Reminders sent to the clinical team via the EMR appear to be an effective means of increasing vaccine uptake and should be considered as part of this year’s drive to vaccinate eligible patients in hospital.

show abstract

“…(6,7) The increased ranking of COVID as a leading cause of death in some age groups is consistent with a downward age shift in the distribution of COVID deaths in last years. (3,8) COVID and Influenza co-infection with other non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis of the ARDs emerge new concern. (9,10) This comorbidity may even increase the disease symptom and mortality rate.…”

Section: Introductionmentioning

confidence: 99%

“…Nonetheless, COVID and Influenza variants continue to evolve and emerge, resulting in significant public concerns worldwide. (3,18) Pharmacologic and bio-vaccine treatment are not always can help to cure the ARDs due to they have a lot of side effects during and post treatment period. Treatment of the ARDs is more difficult in patients with comorbidities as T2D, hypertension, and nonalcoholic steatohepatitis (NASH).…”

Section: Introductionmentioning

confidence: 99%

“…(19)(20)(21) Therefore, searching reliable, secure, and natural methods for treatment of COVID and Influenza are continuing in the worldwide. (3,5,17,18,22) NCDs and COVID are spreading in countries with a higher rate of overweight. (10,(23)(24)(25)(26)(27) The Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy (CALERIE) phase 2 trial showed that moderate reduction of energy intake averaging approximately 12% over 2 years could improve markers of inflammation, cardiometabolic health, and oxidative stress in humans.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Weight loss in patients with COVID-19 and Influenza in comorbidity with NCDs: a pilot prospective clinical trial

Oshakbayev

Durmanova

Idrisov

et al. 2022

Preprint

View full text Add to dashboard Cite

Background COVID and Influenza with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. The aim: to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs. Methods A 6-week open, pilot prospective clinical trial including 62 adult patients with COVID (n=27) and influenza (n=35) in comorbidity with T2D, hypertension, and NASH. Overweight in 33 patients (53.2%) with BMI 28.14±0.39 kg/m2, and 29 patients without overweight with BMI 23.37 ± 0.38 kg/m2. T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); NASH in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients with NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). Primary endpoints Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan. Results The patients with overweight lost -12,4% from baseline or BMI= -4.2 kg/m2, and patients without overweight lost -9,14% from baseline or BMI= -2.2 kg/m2 (-9.7±0.7 kg vs. -6.4±0.6 kg, respectively; P<0.001) at 14-day of the treatment. Weight loss in both groups was due to reduction of fat mass (P<0.0001). Sputum production increased in 1.0-1.5 liter/day on 2-3 days, decreased in 7-9 days. Body temperature normalized in 6-9 days. On 3-5 days, in most patients their urine became turbid/muddy/intensively colored. Urine microscopy showed organic and non-organic salts, and leukocyturia (20-35/sight). White blood cells, lymphocytes, NLR normalized at 14 days (P<0.0001). Total-fibrinogen, C-reactive-protein, and Erythrocyte-sedimentation-rate, ROS normalized at 14-day of treatment (P<0.0001). COVID and Influenza were a negative in >96.3% patients at 14-day. Systolic/diastolic BP decreased (161.3±1.31/101.6±0.85 vs. 118.3±0.46/80.89±0.66, P<0.0001), glucose and lipids metabolism in patients with T2D (n=26) (P<0.0001); ALT and AST in patients with NASH (n=51) were significantly normalized (from baseline 134.3±5.4 and 166.5±5.5 U/L, respectively, and at 14-day to 78.4±4.2 and 92.4±4.9 U/L, respectively (P<0.0001)), platelets increased from baseline (186.5±4.6, ×109/L) at 14-day of treatment (238.5±5.8, ×109/L) (P<0.0001), and at 6-week follow-up (278.3±6.9, ×109/L) (P<0.0001). The mean score of chest-CT for the patients (n=44) was 13.12±0.38 from baseline, and at 14-day the score was 1.72±0.12 (P<0.0001). ROS level normalized at 14-day treatment and 6-week follow-up from baseline (P<0.0001). The previous antidiabetic, antihypertensive, antiinflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-8 days treatment. Conclusions The fast weight loss is clinical/laboratory benefit in treatment of patients with COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH.

show abstract

Influenza Vaccination and COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study

Cited by 10 publications

References 29 publications

Retrospective analysis of COVID-19 among 391 hospitalized patients in the Henan province of China

Retrospective analysis of COVID-19 among 391 hospitalized patients in the Henan province of China

An electronic medical record reminder is independently associated with improved opportunistic influenza vaccination rates for older inpatients

Weight loss in patients with COVID-19 and Influenza in comorbidity with NCDs: a pilot prospective clinical trial

Contact Info

Product

Resources

About